Harris made these remarks in an interview with Fox News
Kamala Harris greets supporters after speaking at a campaign event at Washington Crossing Historic Park on October 16, 2024 in Pennsylvania. (Photo by Anna Moneymaker/Getty Images)
Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
THE US has a broken immigration system that needs to be fixed, vice president Kamala Harris said on Wednesday (16) in a rare interview with a Republican-leaning news channel, during which she sparred with its popular host.
Harris made these remarks in an interview with Fox News anchor Bret Baier.
Baier repeatedly pressed the Democratic presidential nominee on illegal immigration, taxpayer support for gender transition surgery, and other topics closely aligned with former president Donald Trump’s frequent criticisms of her.
With 20 days remaining before the election, Harris attempted to defend her record on immigration and the economy.
When asked how many undocumented immigrants have entered the US illegally under the Biden-Harris administration, Harris did not provide a number.
"Bret, let's just get to the point, OK? The point is that we have a broken immigration system that needs to be repaired," Harris responded.
“So, your Homeland Security Secretary said that 85 per cent of apprehensions...” Baier interjected.
"I'm not finished. We have an immigration system..." Harris tried to continue her answer.
"It's a rough estimate that 6 million people have been released into the country," Baier interrupted again.
“And let me just finish. I'll get to the question, I promise you. I was beginning to answer,” the vice president pleaded.
“When you came into office, your administration immediately reversed a number of Trump-era border policies. Most significantly, the policy required illegal immigrants to be detained until deportation, either in the US or Mexico. You switched that policy. Instead, they were released from custody awaiting trial. Many of these were single adult men, some of whom went on to commit heinous crimes. So, looking back, do you regret the decision to terminate ‘Remain in Mexico’ at the start of your administration?” Baier pressed again.
“At the beginning of our administration, within practically hours of taking office, we introduced a bill to fix our immigration system,” Harris said, as Baier continued to interject.
“We recognised from day one that this is a priority for the nation and the American people. Our focus has been on solving the problem. Since then, we've done several things, including addressing the asylum system, deploying more resources, appointing more judges, tightening penalties for illegal crossings, and securing entry points along the border,” she said.
“We worked on supporting a bipartisan effort, including some of the most conservative members of Congress, to strengthen the border. That bill would have added 1,500 more border agents, which is why Border Patrol agents supported it. It would have helped stem the flow of fentanyl into the US, which is devastating communities across the country."
“Donald Trump learned about the bill and told them to kill it because he preferred political point-scoring over fixing the problem,” Harris alleged.
“This election, in 20 days, will determine whether we have a president who actually cares about solving issues, even when it’s not politically advantageous, because there is a solution,” she said.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.